Cargando…
Vaccine-derived poliovirus serotype 2 outbreaks and response in the Democratic Republic of the Congo, 2017–2021()
Vaccine-derived polioviruses (VDPVs) can emerge from Sabin strain poliovirus serotypes 1, 2, and 3 contained in oral poliovirus vaccine (OPV) after prolonged person-to-person transmission where population vaccination immunity against polioviruses is suboptimal. VDPVs can cause paralysis indistinguis...
Autores principales: | , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Science
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10427717/ https://www.ncbi.nlm.nih.gov/pubmed/36907733 http://dx.doi.org/10.1016/j.vaccine.2023.02.042 |
_version_ | 1785090305756758016 |
---|---|
author | Alleman, Mary M. Jorba, Jaume Riziki, Yogolelo Henderson, Elizabeth Mwehu, Anicet Seakamela, Lerato Howard, Wayne Kadiobo Mbule, Albert Nsamba, Renee Ntumbannji Djawe, Kpandja Yapi, Moïse Désiré Mengouo, Marcellin Nimpa Gumede, Nicksy Ndoutabe, Modjirom Kfutwah, Anfumbom K.W. Senouci, Kamel Burns, Cara C. |
author_facet | Alleman, Mary M. Jorba, Jaume Riziki, Yogolelo Henderson, Elizabeth Mwehu, Anicet Seakamela, Lerato Howard, Wayne Kadiobo Mbule, Albert Nsamba, Renee Ntumbannji Djawe, Kpandja Yapi, Moïse Désiré Mengouo, Marcellin Nimpa Gumede, Nicksy Ndoutabe, Modjirom Kfutwah, Anfumbom K.W. Senouci, Kamel Burns, Cara C. |
author_sort | Alleman, Mary M. |
collection | PubMed |
description | Vaccine-derived polioviruses (VDPVs) can emerge from Sabin strain poliovirus serotypes 1, 2, and 3 contained in oral poliovirus vaccine (OPV) after prolonged person-to-person transmission where population vaccination immunity against polioviruses is suboptimal. VDPVs can cause paralysis indistinguishable from wild polioviruses and outbreaks when community circulation ensues. VDPV serotype 2 outbreaks (cVDPV2) have been documented in The Democratic Republic of the Congo (DRC) since 2005. The nine cVDPV2 outbreaks detected during 2005–2012 were geographically-limited and resulted in 73 paralysis cases. No outbreaks were detected during 2013–2016. During January 1, 2017–December 31, 2021, 19 cVDPV2 outbreaks were detected in DRC. Seventeen of the 19 (including two first detected in Angola) resulted in 235 paralysis cases notified in 84 health zones in 18 of DRC’s 26 provinces; no notified paralysis cases were associated with the remaining two outbreaks. The DRC-KAS-3 cVDPV2 outbreak that circulated during 2019–2021, and resulted in 101 paralysis cases in 10 provinces, was the largest recorded in DRC during the reporting period in terms of numbers of paralysis cases and geographic expanse. The 15 outbreaks occurring during 2017–early 2021 were successfully controlled with numerous supplemental immunization activities (SIAs) using monovalent OPV Sabin-strain serotype 2 (mOPV2); however, suboptimal mOPV2 vaccination coverage appears to have seeded the cVDPV2 emergences detected during semester 2, 2018 through 2021. Use of the novel OPV serotype 2 (nOPV2), designed to have greater genetic stability than mOPV2, should help DRC’s efforts in controlling the more recent cVDPV2 outbreaks with a much lower risk of further seeding VDPV2 emergence. Improving nOPV2 SIA coverage should decrease the number of SIAs needed to interrupt transmission. DRC needs the support of polio eradication and Essential Immunization (EI) partners to accelerate the country’s ongoing initiatives for EI strengthening, introduction of a second dose of inactivated poliovirus vaccine (IPV) to increase protection against paralysis, and improving nOPV2 SIA coverage. |
format | Online Article Text |
id | pubmed-10427717 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Elsevier Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-104277172023-08-17 Vaccine-derived poliovirus serotype 2 outbreaks and response in the Democratic Republic of the Congo, 2017–2021() Alleman, Mary M. Jorba, Jaume Riziki, Yogolelo Henderson, Elizabeth Mwehu, Anicet Seakamela, Lerato Howard, Wayne Kadiobo Mbule, Albert Nsamba, Renee Ntumbannji Djawe, Kpandja Yapi, Moïse Désiré Mengouo, Marcellin Nimpa Gumede, Nicksy Ndoutabe, Modjirom Kfutwah, Anfumbom K.W. Senouci, Kamel Burns, Cara C. Vaccine Article Vaccine-derived polioviruses (VDPVs) can emerge from Sabin strain poliovirus serotypes 1, 2, and 3 contained in oral poliovirus vaccine (OPV) after prolonged person-to-person transmission where population vaccination immunity against polioviruses is suboptimal. VDPVs can cause paralysis indistinguishable from wild polioviruses and outbreaks when community circulation ensues. VDPV serotype 2 outbreaks (cVDPV2) have been documented in The Democratic Republic of the Congo (DRC) since 2005. The nine cVDPV2 outbreaks detected during 2005–2012 were geographically-limited and resulted in 73 paralysis cases. No outbreaks were detected during 2013–2016. During January 1, 2017–December 31, 2021, 19 cVDPV2 outbreaks were detected in DRC. Seventeen of the 19 (including two first detected in Angola) resulted in 235 paralysis cases notified in 84 health zones in 18 of DRC’s 26 provinces; no notified paralysis cases were associated with the remaining two outbreaks. The DRC-KAS-3 cVDPV2 outbreak that circulated during 2019–2021, and resulted in 101 paralysis cases in 10 provinces, was the largest recorded in DRC during the reporting period in terms of numbers of paralysis cases and geographic expanse. The 15 outbreaks occurring during 2017–early 2021 were successfully controlled with numerous supplemental immunization activities (SIAs) using monovalent OPV Sabin-strain serotype 2 (mOPV2); however, suboptimal mOPV2 vaccination coverage appears to have seeded the cVDPV2 emergences detected during semester 2, 2018 through 2021. Use of the novel OPV serotype 2 (nOPV2), designed to have greater genetic stability than mOPV2, should help DRC’s efforts in controlling the more recent cVDPV2 outbreaks with a much lower risk of further seeding VDPV2 emergence. Improving nOPV2 SIA coverage should decrease the number of SIAs needed to interrupt transmission. DRC needs the support of polio eradication and Essential Immunization (EI) partners to accelerate the country’s ongoing initiatives for EI strengthening, introduction of a second dose of inactivated poliovirus vaccine (IPV) to increase protection against paralysis, and improving nOPV2 SIA coverage. Elsevier Science 2023-04-06 /pmc/articles/PMC10427717/ /pubmed/36907733 http://dx.doi.org/10.1016/j.vaccine.2023.02.042 Text en © 2023 Published by Elsevier Ltd. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Article Alleman, Mary M. Jorba, Jaume Riziki, Yogolelo Henderson, Elizabeth Mwehu, Anicet Seakamela, Lerato Howard, Wayne Kadiobo Mbule, Albert Nsamba, Renee Ntumbannji Djawe, Kpandja Yapi, Moïse Désiré Mengouo, Marcellin Nimpa Gumede, Nicksy Ndoutabe, Modjirom Kfutwah, Anfumbom K.W. Senouci, Kamel Burns, Cara C. Vaccine-derived poliovirus serotype 2 outbreaks and response in the Democratic Republic of the Congo, 2017–2021() |
title | Vaccine-derived poliovirus serotype 2 outbreaks and response in the Democratic Republic of the Congo, 2017–2021() |
title_full | Vaccine-derived poliovirus serotype 2 outbreaks and response in the Democratic Republic of the Congo, 2017–2021() |
title_fullStr | Vaccine-derived poliovirus serotype 2 outbreaks and response in the Democratic Republic of the Congo, 2017–2021() |
title_full_unstemmed | Vaccine-derived poliovirus serotype 2 outbreaks and response in the Democratic Republic of the Congo, 2017–2021() |
title_short | Vaccine-derived poliovirus serotype 2 outbreaks and response in the Democratic Republic of the Congo, 2017–2021() |
title_sort | vaccine-derived poliovirus serotype 2 outbreaks and response in the democratic republic of the congo, 2017–2021() |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10427717/ https://www.ncbi.nlm.nih.gov/pubmed/36907733 http://dx.doi.org/10.1016/j.vaccine.2023.02.042 |
work_keys_str_mv | AT allemanmarym vaccinederivedpoliovirusserotype2outbreaksandresponseinthedemocraticrepublicofthecongo20172021 AT jorbajaume vaccinederivedpoliovirusserotype2outbreaksandresponseinthedemocraticrepublicofthecongo20172021 AT rizikiyogolelo vaccinederivedpoliovirusserotype2outbreaksandresponseinthedemocraticrepublicofthecongo20172021 AT hendersonelizabeth vaccinederivedpoliovirusserotype2outbreaksandresponseinthedemocraticrepublicofthecongo20172021 AT mwehuanicet vaccinederivedpoliovirusserotype2outbreaksandresponseinthedemocraticrepublicofthecongo20172021 AT seakamelalerato vaccinederivedpoliovirusserotype2outbreaksandresponseinthedemocraticrepublicofthecongo20172021 AT howardwayne vaccinederivedpoliovirusserotype2outbreaksandresponseinthedemocraticrepublicofthecongo20172021 AT kadiobombulealbert vaccinederivedpoliovirusserotype2outbreaksandresponseinthedemocraticrepublicofthecongo20172021 AT nsambareneentumbannji vaccinederivedpoliovirusserotype2outbreaksandresponseinthedemocraticrepublicofthecongo20172021 AT djawekpandja vaccinederivedpoliovirusserotype2outbreaksandresponseinthedemocraticrepublicofthecongo20172021 AT yapimoisedesire vaccinederivedpoliovirusserotype2outbreaksandresponseinthedemocraticrepublicofthecongo20172021 AT mengouomarcellinnimpa vaccinederivedpoliovirusserotype2outbreaksandresponseinthedemocraticrepublicofthecongo20172021 AT gumedenicksy vaccinederivedpoliovirusserotype2outbreaksandresponseinthedemocraticrepublicofthecongo20172021 AT ndoutabemodjirom vaccinederivedpoliovirusserotype2outbreaksandresponseinthedemocraticrepublicofthecongo20172021 AT kfutwahanfumbomkw vaccinederivedpoliovirusserotype2outbreaksandresponseinthedemocraticrepublicofthecongo20172021 AT senoucikamel vaccinederivedpoliovirusserotype2outbreaksandresponseinthedemocraticrepublicofthecongo20172021 AT burnscarac vaccinederivedpoliovirusserotype2outbreaksandresponseinthedemocraticrepublicofthecongo20172021 |